Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA

EP: 1.Evolving Horizons in HER2-Positive Breast Cancer Care

EP: 2.Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program

EP: 3.Integrating Emerging DESTINY-Breast Data Into HER2+ Treatment Strategies

Now Viewing

EP: 4.Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA

The KATHERINE trial evaluated patients with early HER2-positive breast cancer who had residual disease after neoadjuvant therapy, comparing adjuvant T-DM1 with trastuzumab and demonstrating a marked reduction in recurrence risk. In the metastatic setting, HER2CLIMB-05 is assessing the addition of a CDK4/6 inhibitor to standard HER2-directed therapy, while PATINA examined a maintenance strategy that combines anti-estrogen therapy, dual HER2 blockade, and CDK4/6 inhibition for HER2+/HR+ disease. Together, these trials explore ways to deepen response and prolong disease control across settings. Their strengths include clear patient selection, rational treatment escalation, and clinically meaningful endpoints. Limitations include evolving standards of care, heterogeneous prior therapies, and questions around long-term tolerability and sequencing. Overall, these studies provide important insights that help refine tailored treatment strategies for HER2-positive breast cancer.